Read article A study looking at giving triptorelin every 6 months (GREAT)
This study is looking at giving triptorelin (Decapeptyl) every 6 months instead of every 3 months to treat prostate cancer.
Doctors can treat prostate cancer with surgery, radiotherapy or hormone therapy. This study is looking at men who are having hormone therapy.
Doctors can use the hormone therapy drugs goserelin (Zoladex), leuprorelin (Prostap) and triptorelin (Decapeptyl SR). You usually have these every 3 months. The researchers have developed a new type of triptorelin that you have every 6 months. They want to compare having triptorelin every 6 months with having other hormone therapy drugs every 3 months.
The aims of this trial are to find out
- How well 6 monthly triptorelin works for prostate cancer
- How safe it is to give
- If the men prefer having their hormone therapy every 6 months or every 3 months
Recruitment
Phase
Who can enter
You may be able to enter this study if you
- Have prostate cancer that has spread out of the prostate into surrounding tissue or lymph nodes (locally advanced) or has spread to another part of the body
- Have had a least 2 injections of 3 monthly hormone therapy
- Are at least 18 years old
You cannot enter this study if you
- Have had your testicles removed
- Are taking more than 1 type of hormone therapy for your prostate cancer
- Are having hormone therapy before radiotherapy or with radiotherapy to treat your prostate cancer
- Have had surgery to remove your prostate
- Are having surgery to remove your prostate in the near future
- Are having radiotherapy to relieve symptoms in the near future
- Have had another cancer apart from non melanoma basal cell carcinoma or any other cancer that has been successfully treated and it has not continued to get worse or there has been no sign of it in the last 5 years
- Have had another experimental drug or treatment as part of a clinical trial in the last month or may do so in the near future
- Are allergic to any of the hormone therapy drugs, or their ingredients, that are used in this study
- Have any other medical condition that could affect you taking part in this study
Trial design
This is a phase 4 study. It will recruit 168 men in the UK. This is a randomised study. The men taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in.
The men in group 1 will continue to have their hormone therapy injections every 3 months. The men in group 2 will have their triptorelin hormone injection every 6 months.
The trial team will ask you to fill out 2 questionnaires before you start treatment and at 6 and 12 months during your treatment. The questionnaire will ask about side effects, how you’ve been feeling and how satisfied you are with your current prostate cancer medication. This is called a quality of life study.
Hospital visits
All study visits take place at your general practitioners (GP). How many visits you have will depend on which group are in.
Before taking part in this study everyone will see the doctor for a physical examination and blood tests.
During treatment you see the doctor every 3 months if you are in group 1 and every 6 months if you are in group 2. At 6 and 12 months you have a physical examination and blood tests.
After treatment your doctor will talk to you about which treatment is best for you.
Side effects
The most common side effects of goserelin, leuprorelin and triptorelin are
- Hot flushes and sweating
- Difficulty getting an erection (impotence)
- Weakness
- Feeling sick (nausea)
- Tiredness (fatigue)
- Loss of interest in sex
- Pain in the muscles, joints, back, arms or legs
- Headache
We have more information on goserelin, leuprorelin and triptorelin in our cancer drugs section.
Location of trial
For more information
Please note: we cannot help you to join a specific trial. Unless we state otherwise in this trial summary, you need to print this page and take it to your own doctor to discuss.
Find out how to join a trial or contact our cancer information nurses for other questions about cancer by phone (0808 800 4040), by email, or at
Cancer Research UK
Angel Building
407 St John Street
London
EC1V 4AD
Chief Investigator
Supported by
- Share this: Tweet
-
-
- Print this page
-
Email this page
Increase text size
Decrease text size
Print page
Print basket
Save pages here and print in one go
Looking for leaflets and posters?
How to take part
Read more about how to join a clinical trial
